Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Ph- B-ALL

Outcomes of patients with newly diagnosed CRLF2-rearranged B-ALLПодробнее

The safety and efficacy of hyper-CVAD plus blinatumomab and inotuzumab ozogamicin in Ph- ALLПодробнее

Blinatumomab therapy following hyper-CVAD in B-cell ALLПодробнее

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALLПодробнее

Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in R/R ALLПодробнее

Blinatumomab vs inotuzumab ozogamicin for ALLПодробнее

Updated results of hyper-CVAD and blinatumomab +/- inotuzumab ozogamicin in newly-diagnosed B-ALLПодробнее

The addition of inotuzumab ozogamicin to hyper-CVAD + blinatumomab in patients with B-ALLПодробнее

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-ne...Подробнее

Inotuzumab ozogamicin and blinatumomab prior to and after alloHSCT in R/R Ph+ ALLПодробнее

Safety and efficacy of blinatumomab and inotuzumab ozogamicin in multiple relapsed ALLПодробнее

Update on Phase II study of hyper-CVAD with ponatinib in patients with Ph+ALLПодробнее

Mini-hyper-CVD + InO followed by blina consolidation for R/R ALLПодробнее

Blinatumomab and inotuzumab in children with R/R B-ALLПодробнее

Novel targeted antibodies for R/R B-ALLПодробнее

Blinatumomab plus ponatinib for Ph+ ALLПодробнее

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-n...Подробнее

Real-world outcomes of patients with R/R B-ALL treated with blinatumomab and inotuzumab ozogamicinПодробнее

Long-term follow-up of low-intensity chemotherapy with combination therapy for r/r Ph- acute lym...Подробнее